BACKGROUND: G-protein-coupled receptor kinase 2 (GRK2) is a primary regulator of β-adrenergic signaling in the heart. G-protein-coupled receptor kinase 2 ablation impedes heart failure development, but elucidation of the cellular mechanisms has not been achieved, and such elucidation is the aim of this study. METHODS AND RESULTS: Myocyte contractility, Ca(2+) handling and excitation-contraction coupling were studied in isolated cardiomyocytes from wild-type and GRK2 knockout (GRK2KO) mice without (sham) or with myocardial infarction (MI). In cardiac myocytes isolated from unstressed wild-type and GRK2KO hearts, myocyte contractions and Ca(2+) transients were similar, but GRK2KO myocytes had lower sarcoplasmic reticulum (SR) Ca(2+) content because of increased sodium-Ca(2+) exchanger activity and inhibited SR Ca(2+) ATPase by local protein kinase A-mediated activation of phosphodiesterase 4 resulting in hypophosphorylated phospholamban. This Ca(2+) handling phenotype is explained by a higher fractional SR Ca(2+) release induced by increased L-type Ca(2+) channel currents. After β-adrenergic stimulation, GRK2KO myocytes revealed significant increases in contractility and Ca(2+) transients, which were not mediated through cardiac L-type Ca(2+) channels but through an increased SR Ca(2+). Interestingly, post-MI GRK2KO mice showed better cardiac function than post-MI control mice, which is explained by an improved Ca(2+) handling phenotype. The SR Ca(2+) content was better maintained in post-MI GRK2KO myocytes than in post-MI control myocytes because of better-maintained L-type Ca(2+) channel current density and no increase in sodium-Ca(2+) exchanger in GRK2KO myocytes. An L-type Ca(2+) channel blocker, verapamil, reversed some beneficial effects of GRK2KO. CONCLUSIONS: These data argue for novel differential regulation of L-type Ca(2+) channel currents and SR load by GRK2. G-protein-coupled receptor kinase 2 ablation represents a novel beneficial Ca(2+) handling phenotype resisting adverse remodeling after MI.
BACKGROUND: G-protein-coupled receptor kinase 2 (GRK2) is a primary regulator of β-adrenergic signaling in the heart. G-protein-coupled receptor kinase 2 ablation impedes heart failure development, but elucidation of the cellular mechanisms has not been achieved, and such elucidation is the aim of this study. METHODS AND RESULTS: Myocyte contractility, Ca(2+) handling and excitation-contraction coupling were studied in isolated cardiomyocytes from wild-type and GRK2 knockout (GRK2KO) mice without (sham) or with myocardial infarction (MI). In cardiac myocytes isolated from unstressed wild-type and GRK2KO hearts, myocyte contractions and Ca(2+) transients were similar, but GRK2KO myocytes had lower sarcoplasmic reticulum (SR) Ca(2+) content because of increased sodium-Ca(2+) exchanger activity and inhibited SR Ca(2+) ATPase by local protein kinase A-mediated activation of phosphodiesterase 4 resulting in hypophosphorylated phospholamban. This Ca(2+) handling phenotype is explained by a higher fractional SR Ca(2+) release induced by increased L-type Ca(2+) channel currents. After β-adrenergic stimulation, GRK2KO myocytes revealed significant increases in contractility and Ca(2+) transients, which were not mediated through cardiac L-type Ca(2+) channels but through an increased SR Ca(2+). Interestingly, post-MI GRK2KO mice showed better cardiac function than post-MI control mice, which is explained by an improved Ca(2+) handling phenotype. The SR Ca(2+) content was better maintained in post-MI GRK2KO myocytes than in post-MI control myocytes because of better-maintained L-type Ca(2+) channel current density and no increase in sodium-Ca(2+) exchanger in GRK2KO myocytes. An L-type Ca(2+) channel blocker, verapamil, reversed some beneficial effects of GRK2KO. CONCLUSIONS: These data argue for novel differential regulation of L-type Ca(2+) channel currents and SR load by GRK2. G-protein-coupled receptor kinase 2 ablation represents a novel beneficial Ca(2+) handling phenotype resisting adverse remodeling after MI.
Authors: Xiongwen Chen; Hiroyuki Nakayama; Xiaoying Zhang; Xiaojie Ai; David M Harris; Mingxin Tang; Hongyu Zhang; Christopher Szeto; Kathryn Stockbower; Remus M Berretta; Andrea D Eckhart; Walter J Koch; Jeffery D Molkentin; Steven R Houser Journal: J Mol Cell Cardiol Date: 2010-11-25 Impact factor: 5.000
Authors: Katharina Foerster; Tomas Kaeferstein; Ferdi Groner; Stefan Engelhardt; Jan Matthes; Walter J Koch; Martin J Lohse; Stefan Herzig Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2004-04-09 Impact factor: 3.000
Authors: H A Rockman; K R Chien; D J Choi; G Iaccarino; J J Hunter; J Ross; R J Lefkowitz; W J Koch Journal: Proc Natl Acad Sci U S A Date: 1998-06-09 Impact factor: 11.205
Authors: Hiroyuki Nakayama; Xiongwen Chen; Christopher P Baines; Raisa Klevitsky; Xiaoying Zhang; Hongyu Zhang; Naser Jaleel; Balvin H L Chua; Timothy E Hewett; Jeffrey Robbins; Steven R Houser; Jeffery D Molkentin Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Priscila Y Sato; J Kurt Chuprun; Laurel A Grisanti; Meryl C Woodall; Brett R Brown; Rajika Roy; Christopher J Traynham; Jessica Ibetti; Anna M Lucchese; Ancai Yuan; Konstantinos Drosatos; Doug G Tilley; Erhe Gao; Walter J Koch Journal: Sci Signal Date: 2018-12-11 Impact factor: 8.192
Authors: Brooke M Ahern; Bryana M Levitan; Sudhakar Veeranki; Mihir Shah; Nemat Ali; Andrea Sebastian; Wen Su; Ming C Gong; Jiayang Li; Julian E Stelzer; Douglas A Andres; Jonathan Satin Journal: J Biol Chem Date: 2019-05-30 Impact factor: 5.157